News >

NICE Recommends Ibrutinib for Relapsed/Refractory MCL

Jason Harris
Published: Friday, Dec 15, 2017

Blood.jpg The United Kingdom's National Institute for Health Care and Excellence (NICE) has published new guidelines recommending ibrutinib (Imbruvica) as treatment for patients with relapsed/refractory mantle cell lymphoma (MCL).

“Imbruvica continues to provide a beneficial treatment option for patients with relapsed/refractory mantle cell lymphoma," Thorsten Graef, MD, PhD, head of clinical development, Pharmacyclics, said in a news release. “Prior to the discovery and introduction of Imbruvica, people diagnosed with MCL had limited treatment options. This long-term data analysis adds to our growing understanding of Imbruvica's potential treatment benefits for previously treated MCL patients.”
Rule S, Dreyling M, Goy A, et al. Median 3.5-year follow-up of ibrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: a pooled analysis. In: Proceedings from the 59th ASH Annual Meeting and Exposition; December 9-12, 2017; Atlanta, Georgia. Abstract 151.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x